Picosecond Infrared Laser Desorption Mass Spectrometry Identifies Medulloblastoma Subgroups on Intrasurgical Timescales

Abstract

Medulloblastoma (MB) is a pediatric malignant brain tumor composed of four different subgroups (WNT, SHH, Group 3, Group 4), each of which are a unique biological entity with distinct clinico-pathological, molecular, and prognostic characteristics. Although risk stratification of patients with MB based on molecular features may offer personalized therapies, conventional subgroup identification methods take too long and are unable to deliver subgroup information intraoperatively. This limitation prevents subgroup-specific adjustment of the extent or the aggressiveness of the tumor resection by the neurosurgeon. In this study, we investigated the potential of rapid tumor characterization with Picosecond infrared laser desorption mass spectrometry (PIRL-MS) for MB subgroup classification based on small molecule signatures. One hundred and thirteen ex vivo MB tumors from a local tissue bank were subjected to 10- to 15-second PIRL-MS data collection and principal component analysis with linear discriminant analysis (PCA-LDA). The MB subgroup model was established from 72 independent tumors; the remaining 41 de-identified unknown tumors were subjected to multiple, 10-second PIRL-MS samplings and real-time PCA-LDA analysis using the above model. The resultant 124 PIRL-MS spectra from each sampling event, after the application of a 98.9% correct classification rate. Post-ablation histopathologic analysis suggested that intratumoral heterogeneity or sample damage prior to PIRL-MS sampling at the site of laser ablation was able to explain failed classifications. Therefore, upon translation, 10-seconds of PIRL-MS sampling is sufficient to allow personalized, subgroup-specific treatment of MB during surgery.

Significance: This study demonstrates that laser-extracted lipids allow immediate grading of medulloblastoma tumors into prognostically important subgroups in 10 seconds, providing medulloblastoma pathology in an actionable manner during surgery.

Introduction

Medulloblastoma (MB) is a heterogeneous posterior fossa malignancy that accounts for about 10% to 20% of all pediatric brain tumors (1–3). The heterogeneity in MB manifests itself in four known subgroups, named WNT (Wingless/integrated), SHH (Sonic HedgeHog), Group 3 and Group 4 (1, 4). According to genomic analyses each MB subgroup is a distinct tumor entity that consequently carries its own molecular, as well as clinico-pathological features (5–7). MB subgroups exhibit different survival rates (6), risk of recurrence (8), and likelihood of favorable response (9) to the standard multimodal therapy comprised of maximal safe resection, chemotherapy and, for patients older than 3 years of age, cranio-spatial irradiation (10, 11). The standard risk stratification of MB patients into average and high-risk groups takes into consideration patient’s age, presence of disseminated disease at diagnosis, and size of postoperative residual tumor (9).

Currently, due to the long turnaround times of the existing MB subgrouping methods of IHC and genomic analyses (12), subgroup information is not available during tumor resection. In keeping with this, the standard of care is based on the traditional risk stratification and the patient’s age at the time of diagnosis and does not take into consideration MB subgroup information in planning surgical resection extents (13). All patients undergo a maximum safe resection surgery to debulk the tumor and alleviate the symptoms, followed by adjuvant chemo- and age-dependent radiotherapy (10, 14). The discovery of molecular MB subgroups,
however, has paved the way for a paradigm shift in MB subgroup specific treatment planning as evidenced by a new risk stratification method that takes into consideration the prognostic and survival information for each MB subgroup (9, 15). In this context, real-time subgrouping of MB tumors for molecularly informed clinical trials has been proposed (9). In a similar vein, a number of clinical trials (NCT02066220, NCT01878617, NCT02724579) are underway to validate de-escalation of adjuvant therapy suggested for low-risk patients with MB such as those with the nonmetastatic WNT subgroup tumors (16). The motivation behind these trials is to reduce treatment-related complications in patients with MB with favorable outcomes (9). At the moment, there is no evidence in the literature to suggest that said low-risk patients with MB above could also benefit from less aggressive surgery. The ability to determine MB subgroup information intraoperatively, however, is likely to motivate further assessments that may lead to subsequent development of subgroup specific surgical treatments in much the same way that the explorations of the validity of de-escalated adjuvant methods for low-risk patients with MB was made possible by the availability of MB subgroup information prior to adjuvant therapy planning. Recent advances in molecular classifications of MB (17–19) thus create a demand for a rapid screening tool that can resolve said molecular heterogeneities within the time constraints of surgical resection for potential future use in personalized surgery, even if those approaches cannot be envisioned in the context of the current standard of care.

Tissue small molecule profiling with a variety of ambient mass spectrometry (MS) technologies (20) such as matrix-assisted laser desorption and ionization mass spectrometry (e.g., iKnife; refs. 27, 28), Spider-Mass (29), and the MassSpec pen (30) have been reported to have utility in rapid tissue identification. These techniques utilize collective changes in the lipidome and metabolome to probe molecular differences that give rise to the unique identity of each cancer type. Capitalizing on the success of these discoveries, and in the quest to deliver MB subgroup information in an actionable manner during surgery, our group has published a xenograft-based, limited feasibility assessment of a handheld laser mass spectrometry probe that can classify Group 3 and SHH MB in only ~5 to 10 seconds of sampling followed with post acquisition offline data analysis (31). The probe is composed of a picosecond infrared laser (PIRL) fiber that vaporizes tumor lipid and small molecule metabolites (32) for subsequent capture and analysis by means of MS. The classification of the subcutaneous xenograft SHH and Group 3 MB tumors into their respective subclasses was achieved by comparing, using multivariate statistical methods, the PIRL-MS signatures of small molecules in unknown tumors against those of a Group 3 and SHH MB signature library (31). Our previous study provided proof-of-principle for the utility of PIRL-MS in distinguishing only Group 3 and SHH MB (31), an observation that in this manuscript is being extended to all four MB subgroups using clinical patient samples. Additionally, our previous study (31) utilized post acquisition assessments of the processed PIRL-MS spectra using off-line statistical analysis platforms, and did not allow real-time (i.e. as PIRL-MS spectra were acquired) analysis and delivery of MB subgroup classification results in a simplified manner. Real-time analysis of mass spectra poses additional technical challenges not addressed in our previous work (31) that used off-line analysis, and processed spectra. The inaccessibility of data processing techniques, such as centroid fitting, requires implementation of alternative data processing and analysis methods. Therefore, to further evaluate the translational potential of PIRL-MS as a sampling tool to reveal MB subgroup information intraoperatively within seconds, this study uses real-time multivariate analysis of PIRL-MS spectra with simplified display of the MB subgroup classification results, and provides an extension of the utility of PIRL-MS to classify all four MB subgroups using human patient samples, as opposed to xenografts. In this work we report small molecule signatures of all four MB subgroups accessed by PIRL-MS sampling, along with molecular identities of the MB subgroup classifying lipids. Our evaluation of the performance of the PIRL-MS probe in classifying MB subgroups with only 10 seconds of sampling and analysis time was performed using 113 independent banked ex vivo patient samples, and we demonstrate 98.9% accuracy in subgroup determination. We further report the utility of a real-time multivariate statistical analysis platform previously used for simple display of molecular pathology results such as cancer type or subtype using MS analysis of electrocautery plume (27), for MB subgroup identification with PIRL-MS. We further discuss the reproducibility, duty cycle, misclassification rate, and intra-sample performance variation metrics of the PIRL-MS platform. These insights are relevant for future adoption and potential clinical use. The overarching goal of our PIRL-MS technology development is to improve patient quality of life by making the wealth of prognostic information present within MB subgroups available to neurosurgeons such that this information can be combined with other surgical risk factors towards an personalized approach for patients with MB.

**Materials and Methods**

**PIRL-MS data collection**

A subset of 120 snap frozen MB samples gathered through Medulloblastoma Advanced Genomics International Consortium (MAGIC; ref. 33) from 30 participating centers in north America, Europe, and Asia was accessed via the Hospital for Sick Children (Toronto; ref. 17) for this study. This set thus captures some level of demographic biological variability despite its small size. The details of the sample collection and handling prior to PIRL-MS sampling are included in the Supplementary Information. These samples (~1–6 mm³) were obtained under Research Ethics Board approval with informed written consent; 1000057113 (Hospital for Sick Children), 17-5298 (University Health Network), 17-101 (St Michael’s Hospital), and 00035377 (Ontario Institute for Cancer Research). Samples were cut on a dry ice bed, and transported on dry ice to the PIRL-MS sampling site, and thawed for ~30 seconds before laser sampling inside a biological safety cabinet. The subgroups were known via previous NanoString assessment (34) or DNA Methylation assays, taken as “gold standard” classification (35). The description of the experimental laser setup and MS collection geometry is identical to previous work (31, 32). A PIRL operating at 1 kHz outputting ~240 mW at 3,000 nm with pulse duration of ~300 picoseconds was used. The PIRL fiber with a diameter of ~0.45 mm was held 1 to 2 mm away from the surface of the ex vivo tissue with the tip of the ~2 mm long Tygon collection tube at close (<2 mm) proximity to the ablation site. Supplementary Fig. S1 illustrates the collection geometry of the PIRL-MS setup described previously (32), also used herein. This study did not consider any other variables

www.aacnjournals.org
such as patient demographics, clinic of sample origin, transit or storage time, and only used subgroup information of said samples as the sole variable.

Principal component analysis-linear discriminant analysis modeling

The PIRL-MS signature models for all four MB subgroups were built using principal component analysis-linear discriminant analysis (PCA-LDA) on an "Abstract Model Builder" (AMX; version 1.0.1360.0) platform from Waters Research Centre. The PIRL-MS spectral data from Waters' MassLynx (version 4.1) software were imported directly into AMX, as recently implemented using closely related versions of this program for the classification of biological samples (36). The AMX platform offers a "model building" component where PCA-LDA analysis is used to create a multivariate model of the tissue molecular signatures, alongside a "recognition" component where blind/unknown samples can be scored against the model for classification. In this manuscript, the model was validated using blind tests. All ~15 second PIRL-MS sampling events from a given piece of tissue, contained in a single file, were then separately selected on AMX based on the rise of base peak intensity that occurred upon laser sampling where we applied a threshold of greater than 5 × 10^3 a.u. Additionally, samples with less than 3 seconds of persistent MS signal were excluded.

All spectral data from selected sampling events in the m/z range of 500 to 1,000 Da were put into 0.1 m/z bins and subjected to PCA-LDA analysis by AMX. The number of PCA dimensions for the model (~20% of the total number of data points in the model) was 35, with three linear dimensions. The m/z range of 717.5067 (C39H74O9P), which is represented strongly in all samples, was used to correct mass shifts (lock mass). All spectra were normalized by the total ion count (TIC). For the low complexity model we used the "peak list based PCA-LDA model" function on the AMX platform and same PCA-LDA settings as above. The mass tolerance for the peak list was set to 0.2 Da. The cross-validations via 20% leave out tests were performed using AMX with 3 × standard deviation as the boundary condition (to classify a data point as unclassifiable or outlier). The model building used ~15 second sampling events, and the classification at most 10 seconds of sampling.

Real-time analysis of the unknown blind samples with AMX

For real-time analysis of MB subgroups we used the "AMX recognition" component, using the same lock mass and boundary conditions as above. The intensity limit was set to TIC = 2 × 10^6 a.u. to determine the time stamp for including an MS scan in the multivariate comparison. The "number of scans per spectrum" was set to 12 scans, and "wait for good spectrum timeout" value was 12 seconds. This meant that when the TIC rose to a value above 2 × 10^5 AMX started to count the MS scans until 12 seconds passed, averaging all of the spectra in this 12-second window. This average spectrum was then sent to the recognition algorithm for comparison with the uploaded PCA-LDA model and prediction of the MB subgroup of the unknown data point. The probability threshold was initially set at 0% and then increased to 90% and 95% to increase the stringency of the predictions. MB subgroup assignments from AMX were available within ~1 second after the collection of the laser plume.

Identification of MB classifying lipids from LC/MS-MS analysis of the PIRL plume

The capture and extraction of PIRL-MS laser plume was completed as described previously (31). For direct tissue extract comparisons, an 8 mm^3 piece of tissue was sliced off and carefully applied onto the filter paper, and subjected to the same extraction method as the laser plume, according to the publication above. The chromatographic separation was performed on an ACQUITY UPLC-I-Class system coupled to a Waters Synapt G2-S Q-TOF-MS using conditions described in further detail in Supplementary Information.

Results

Building a statistical model for MB molecular signatures

To create a statistical model that describes MS profiles of all four MB subgroups, we subjected 75 human MB tumors (16 WNT, 20 SHH, 19 Group 3, and 20 Group 4) to ~15 seconds of PIRL-MS sampling. Inspection of the raw data (i.e., mass spectra; Supplementary Fig. S2) suggested that the PIRL-MS spectra of MB subgroups differed from one another only in terms of alterations in the abundance of small molecules, particularly in the mass to charge ratio (m/z) range of 500 to 1,000 Da. To tease out subtle changes in the small molecule abundances that could be used to identify MB subgroups, we subjected the PIRL-MS spectra (mass range of 500–1,000 Da) to a tandem of PCA-LDA. The resultant PCA-LDA model (Fig. 1A) was composed of 190 sampling events (i.e., PIRL-MS spectra or data points) collected in ~15 seconds from 15 WNT, 19 SHH, 18 Group 3, and 20 Group 4 MB (a total of 72 cancer cases from which we were able to extract good quality data upon application of exclusion criteria described in the legend of Supplementary Fig. S3). This model shows good statistical separation of the data points that belonged to each subgroup. Supplementary Table S1 summarizes the sampling period, and signal intensity values for the PIRL-MS sampling events used to build the model.

The separate grouping, in the PCA-LDA space, of the model's 190 data points based on subgroup information (Fig. 1A) attests to the specificity of PIRL-MS to identify molecular signatures specific to each MB subgroup. Fig. 1B shows the loading plots of each of the three linear dimensions of the PCA-LDA model. These plots rank the univariate m/z values (or mass spectral peaks) in terms of their contributions to the statistical discrimination between MB subgroups shown in Fig. 1A. The m/z values (on the "x" axis) are ranked (on the "y" axis) based on the extent they change intensity between subgroups, with those that lie farthest from the y = 0 line contributing the most. In this plot, m/z values that contribute most strongly to the statistical discrimination between MB subgroups are highlighted (see Supplementary Table S2 for the list). In Supplementary Fig. S4, we show that this limited m/z list is sufficient to statistically discriminate between all four MB subgroups.

Assessment of the robustness of the model by 20% leave out test

The robustness of the model in Fig. 1A was assessed using a 20% leave out and remodel test, where 20% of the data were iteratively excluded from the model, which was then subsequently built using the remaining 80%. The 20% "pseudo-unknowns" were then ranked for correct classification into their expected MB subgroups. The resultant misclassification rate is only interpreted to indicate robustness (the model itself is validated via blind tests.
Table 1 summarizes the results, suggesting a small 4.2% misclassification rate (8 of 190) and only 5.8% unclassifiable data points that did not classify to any of the 4 MB subgroups (11 of 190). Therefore, the model is highly robust as the majority of the data points consistently classified correctly to their respective MB subgroups. A confusion matrix is also included to indicate the breakdown, per MB subgroup, of correctly classified, unclassifiable, and misclassified data points (Table 1). As can be seen here, Group 3 and Group 4 MB showed the highest chance of misclassification. This is consistent with previous studies that have reported misclassifications between these two groups, due to genomic similarities (17).

**Classifying unknown MB tumors in a blind test using the teachings of the model**

To validate the model developed above, and to address potential shortcomings of the 20% leave-out-and-remodel strategy, such as redundancies in the number of biological replicates, 45
de-identified MB samples not used in building the model with subgroup breakdowns of SHH (n = 10), WNT (n = 10), Group 3 (n = 12), and Group 4 (n = 13) were subjected to 10-second sampling, and assessment against the MB subgroup model shown in Fig. 1A. The PIRL-MS operator(s) were blinded to the subgroup information during data collection and analysis. Except for four very small (~1 mm3) WNT samples that visibly turned into liquid upon being thawed, from which we could not recover any PIRL-MS spectra, no other data points were excluded from the analysis. Supplementary Table S3 lists the prediction results for each of the resultant 124 sampling events from the 41 de-identified samples that could be analyzed. As shown here, the average sampling time of 7.4 ± 2.2 seconds corresponded to an average TIC value of (2.6 ± 1.3) × 105. This signal strength is comparable to the value of (2.5 ± 1.3) × 105 for the model itself, obtained under 14 ± 4 seconds of sampling (Supplementary Table S1), indicating reproducibility.

Table 2 provides a summary of the blind sample classification scores listed in Supplementary Table S3. Out of the total of 124 sampling events examined, 101 reported correct classifications, 7 data points were misclassified, 8 data points were of poor quality, and 8 data points were unclassifiable. Excluding the unclassifiable and poor quality data points (16 events) that could be remedied by performing additional 10-second samplings, 108 classifiable data points were generated. We report a base correct classification rate of 93.5% (101 correct assignments) over the total 108 classifiable data points. To further improve this rate, we utilized probability values available for each PCA-LDA classification (Supplementary Table S3) to re-evaluate the blind sample assessments above. Through applying various probability thresholds for PCA-LDA classification, we were able to make MB subgroup predictions of the blind samples more stringent. As illustrated in Table 2, the application of 90% and 95% thresholds increases the correct classification rate to 95.9% and 98.9% respectively, which is an improvement from the base value of 93.5% for the nonthresholded predictions. As shown in this table, the increased stringency of the prediction leads to a larger number of unclassifiable data points from 8 (nonthresholded) to 18 (90% threshold), and to 28 for the 95% probability threshold. This change is accompanied with a concomitant decrease in the number of misclassified sampling events from seven (nonthresholded) to four (90% threshold) such that at 95% probability threshold only a single sampling event is misclassified. Therefore, increasing the stringency of the predictions constitutes a good compromise to reduce the number of misclassifications.


dieded MB samples not used in building the model with subgroup breakdowns of SHH (n = 10), WNT (n = 10), Group 3 (n = 12), and Group 4 (n = 13) were subjected to 10-second sampling, and assessment against the MB subgroup model shown in Fig. 1A. The PIRL-MS operator(s) were blinded to the subgroup information during data collection and analysis. Except for four very small (~1 mm3) WNT samples that visibly turned into liquid upon being thawed, from which we could not recover any PIRL-MS spectra, no other data points were excluded from the analysis. Supplementary Table S3 lists the prediction results for each of the resultant 124 sampling events from the 41 de-identified samples that could be analyzed. As shown here, the average sampling time of 7.4 ± 2.2 seconds corresponded to an average TIC value of (2.6 ± 1.3) × 105. This signal strength is comparable to the value of (2.5 ± 1.3) × 105 for the model itself, obtained under 14 ± 4 seconds of sampling (Supplementary Table S1), indicating reproducibility.

Table 2 provides a summary of the blind sample classification scores listed in Supplementary Table S3. Out of the total of 124 sampling events examined, 101 reported correct classifications, 7 data points were misclassified, 8 data points were of poor quality, and 8 data points were unclassifiable. Excluding the unclassifiable and poor quality data points (16 events) that could be remedied by performing additional 10-second samplings, 108 classifiable data points were generated. We report a base correct classification rate of 93.5% (101 correct assignments) over the total 108 classifiable data points. To further improve this rate, we utilized probability values available for each PCA-LDA classification (Supplementary Table S3) to re-evaluate the blind sample assessments above. Through applying various probability thresholds for PCA-LDA classification, we were able to make MB subgroup predictions of the blind samples more stringent. As illustrated in Table 2, the application of 90% and 95% thresholds increases the correct classification rate to 95.9% and 98.9% respectively, which is an improvement from the base value of 93.5% for the nonthresholded predictions. As shown in this table, the increased stringency of the prediction leads to a larger number of unclassifiable data points from 8 (nonthresholded) to 18 (90% threshold), and to 28 for the 95% probability threshold. This change is accompanied with a concomitant decrease in the number of misclassified sampling events from seven (nonthresholded) to four (90% threshold) such that at 95% probability threshold only a single sampling event is misclassified. Therefore, increasing the stringency of the predictions constitutes a good compromise to reduce the number of misclassifications.

Origin of failed classifications

To further understand the basis for the origin of failed classification scores listed in Supplementary Table S3, we used post-PIRL-MS pathology assessments to provide a case-by-case evaluation of the origins of misclassification and unclassifiable data points using the nonthresholded data as the basis for our comparison. Supplementary Fig. S5A–S5K provides the pathology scores.
Rapid Determination of Medulloblastoma Subgroups

<table>
<thead>
<tr>
<th>Target m/z (binned data)</th>
<th>PCA-LDA rank</th>
<th>LC/MS (m/z)</th>
<th>RT (min)</th>
<th>Theoretical m/z</th>
<th>Error (ppm)</th>
<th>Ion form</th>
<th>Assignment</th>
<th>Predicted formula</th>
<th>Distinguishing fragments (ms/ms)</th>
</tr>
</thead>
<tbody>
<tr>
<td>572.45</td>
<td>5 (LD2)</td>
<td>572.4811</td>
<td>7.8</td>
<td>572.4815</td>
<td>0.7</td>
<td>[M+Cl]^+</td>
<td>Cer(d53:4)</td>
<td>[C47H82O13P]^+</td>
<td>m/z 237, m/z 280, m/z 308, m/z 506</td>
</tr>
<tr>
<td>628.55</td>
<td>6 (LD3)</td>
<td>628.5429</td>
<td>12.9</td>
<td>628.5441</td>
<td>1.9</td>
<td>[M+Cl]^+</td>
<td>Cer(d53:4)</td>
<td>[C45H77NO7P]^+</td>
<td>m/z 295, m/z 356</td>
</tr>
<tr>
<td>656.55</td>
<td>4 (LD4)</td>
<td>656.5744</td>
<td>7.1</td>
<td>656.5754</td>
<td>1.5</td>
<td>[M+Cl]^+</td>
<td>Cer(d40:4)</td>
<td>[C41H77NO7P]^+</td>
<td>m/z 237, m/z 321, m/z 364, m/z 380</td>
</tr>
<tr>
<td>716.55</td>
<td>3 (LD1)</td>
<td>716.5199</td>
<td>6.11</td>
<td>716.5236</td>
<td>6.28</td>
<td>[M-CH3]^+</td>
<td>Cer(d53:4)</td>
<td>[C45H77NO7P]^+</td>
<td>m/z 227, m/z 281</td>
</tr>
<tr>
<td></td>
<td></td>
<td>716.5233</td>
<td>6.24</td>
<td>716.5266</td>
<td>0.4</td>
<td>[M-CH3]^+</td>
<td>Cer(d53:4)</td>
<td>[C45H77NO7P]^+</td>
<td>m/z 253, m/z 295</td>
</tr>
<tr>
<td></td>
<td></td>
<td>716.5218</td>
<td>6.38</td>
<td>716.5256</td>
<td>2.5</td>
<td>[M-CH3]^+</td>
<td>Cer(d53:4)</td>
<td>[C45H77NO7P]^+</td>
<td>m/z 253, m/z 295</td>
</tr>
<tr>
<td></td>
<td></td>
<td>716.5208</td>
<td>6.78</td>
<td>716.5236</td>
<td>3.9</td>
<td>[M-CH3]^+</td>
<td>Cer(d53:4)</td>
<td>[C45H77NO7P]^+</td>
<td>m/z 253, m/z 295</td>
</tr>
<tr>
<td>742.55</td>
<td>5 (LD3)</td>
<td>742.5362</td>
<td>6.48</td>
<td>742.5392</td>
<td>4</td>
<td>[M-CH3]^+</td>
<td>Cer(d53:4)</td>
<td>[C45H77NO7P]^+</td>
<td>m/z 255, m/z 281</td>
</tr>
<tr>
<td>742.55</td>
<td>5 (LD3)</td>
<td>742.5362</td>
<td>6.48</td>
<td>742.5392</td>
<td>4</td>
<td>[M-CH3]^+</td>
<td>Cer(d53:4)</td>
<td>[C45H77NO7P]^+</td>
<td>m/z 255, m/z 279</td>
</tr>
<tr>
<td>748.55</td>
<td>3 (LD2)</td>
<td>748.5267</td>
<td>7.43</td>
<td>748.5287</td>
<td>2.7</td>
<td>[M-H]^−</td>
<td>PE(38:4)</td>
<td>[C45H77NO7P]^−</td>
<td>m/z 303, m/z 444, m/z 462</td>
</tr>
<tr>
<td>750.55</td>
<td>2 (LD1)</td>
<td>750.5443</td>
<td>8.99</td>
<td>750.5453</td>
<td>1.7</td>
<td>[M-H]^−</td>
<td>PE(38:4)</td>
<td>[C45H77NO7P]^−</td>
<td>m/z 331, m/z 436</td>
</tr>
<tr>
<td></td>
<td></td>
<td>750.5414</td>
<td>9.68</td>
<td>750.5453</td>
<td>1.9</td>
<td>[M-H]^−</td>
<td>PE(38:4)</td>
<td>[C45H77NO7P]^−</td>
<td>m/z 303, m/z 446, m/z 464</td>
</tr>
<tr>
<td>766.55</td>
<td>2 (LD3)</td>
<td>766.5352</td>
<td>6.28</td>
<td>766.5392</td>
<td>5.2</td>
<td>[M-CH3]^+</td>
<td>PC(36:4)</td>
<td>[C45H77NO7P]^+</td>
<td>m/z 255, m/z 303</td>
</tr>
<tr>
<td></td>
<td></td>
<td>766.5372</td>
<td>8.59</td>
<td>766.5392</td>
<td>2.6</td>
<td>[M-H]^−</td>
<td>PE(38:4)</td>
<td>[C45H77NO7P]^−</td>
<td>m/z 283, m/z 303</td>
</tr>
<tr>
<td>774.55</td>
<td>7 (LD3)</td>
<td>774.5442</td>
<td>9.32</td>
<td>774.5454</td>
<td>2.5</td>
<td>[M-H]^−</td>
<td>PE(40:6)</td>
<td>[C45H77NO7P]^−</td>
<td>m/z 327, m/z 426, m/z 464</td>
</tr>
<tr>
<td>885.55</td>
<td>7 (LD3)</td>
<td>885.5489</td>
<td>6.7</td>
<td>885.5499</td>
<td>4.4</td>
<td>[M-H]^−</td>
<td>PI(58:4)</td>
<td>[C45H84O2P]^−</td>
<td>m/z 283, m/z 303</td>
</tr>
</tbody>
</table>

Table 3. Identification of MB subgroup classifying molecules from LC/MS-MS analysis

- **NOTE:** This table lists the target mass (from binned PIRL-MS data, 0.1 m/z; on a Xevo q-ToF), accurate mass (from LC/MS on high-resolution Synapt), retention times (from LC) as well as mass shift (error ppm) from comparison of the experimental and theoretical mass [LipidMaps(37)], ion form, fragmentation pattern from MS-MS data as well as rank order by which each identified molecule contributes to the PCA-LDA discrimination of MB subgroups. All identified molecules contribute strongly to discrimination of MB subgroups as shown by the indicated rank order in each linear dimension (Fig. 1B). We have also shown distinguishing fragments from MS-MS analysis used to provide lipid chain assignments. Predicted chemical formulas were determined based on accurate mass, elemental composition analysis (MassLynx) and LipidMaps database search. Representative PIRL-MS spectra from q-ToF were subjected to lock mass correction and used as a guide to determine corresponding LC/MS m/z values from Synapt.

- **a**Two isobaric lipids were co-eluted.

annotations for all sampling events that were misclassified or were unclassifiable using the PIRL-MS model of MB subgroups (Fig. 1A). As illustrated in the legend that accompanies Supplementary Fig. S5, the aberrantly high ratios of stroma that localized to the sampling sites as well as infiltration of healthy brain tissue, likely not accounted for in the MB subgroup model used, can explain the origin of most misclassifications and many of the unclassifiable data points. Although the demonstrated hypersensitivity of PIRL-MS to molecular heterogeneity at the sampling sites attests to its superb specificity, more extensive PIRL-MS models that take signatures of stroma as well as healthy brain tissue into consideration may be required to reduce the number of failed classifications.

To further show the correlation between hypersensitive extractions of MB classifying signatures and tissue morphology at the sampled regions, in Supplementary Fig. S6A we examined the statistical similarity between the PIRL-MS profiles of misclassified/unclassifiable data points and those that correctly classified into their respective MB subgroups. Here, we used PCA-LDA score plots to compare the PIRL-MS profiles of these two data groups. As illustrated here, the misclassified and unclassifiable data points possessed distinct PIRL-MS profiles compared with correctly classified data points with heavily damaged sample 1266, stroma-rich samples 2636 and 2100, as well as healthy brain tissue containing sample 2378 being most statistically different from the correctly classified data points (Supplementary Fig. S5). Here, the data points that lie too close to the multivariate space populated with correctly classified data points may misclassify, and those that are most dissimilar will remain unclassifiable. In keeping with this observation, the application of the 95% probability threshold to make the predictions more stringent is shown to eliminate all but one of the misclassified data points (Table 2). In the absence of more extensive models inclusive of a broader range of heterogeneity signatures suggested above, thresholding predictions seems effective to mitigate misclassifications in MB. Here, we speculate that the concomitant increase in the number of unclassifiable data points that arise as a consequence of enhancing the stringency of the predictions may be remedied by performing additional 5 to 10 second samplings. To validate the clustering of the misclassified/unclassifiable data points and the correctly classified ones in Supplementary Fig. S6A, we also created a four-member PCA-LDA model that possessed randomly scrambled spectra from each MB subgroup. The randomly grouped MB data points (Supplementary Fig. S6B) show no statistical discrimination once subjected to PCA-LDA assessment. Therefore, the separation seen in Supplementary Fig. S6A, indicative of the role of tumor heterogeneity in model failure, is a valid observation. In addition, lack of statistical grouping of randomized data in Supplementary Fig. S6B also suggests significant overfitting of the PIRL-MS data by AMX is unlikely to be taking place in other multivariate examinations presented in this work.

Identification of MB classifying molecules with plume capture and high-resolution MS analysis

To determine the molecular identities of the MB subgroup classifying lipids through a targeted approach, we captured the plume of the PIRL desorption on a filter paper using a representative Group 4 MB tumor (sample ID 1365) that contained all of the 44 m/z values identified above to drive MB subgroup separation (Fig. 1B, Supplementary Table S2). The filter paper containing the laser extracted tissue molecules was then subjected to chemical extraction of lipids followed by analysis with high-resolution MS after LC using protocols developed and published previously (31). We also performed MS-MS analysis to further narrow down the lipid chain assignments using known lipid fragmentation patterns (37). To demonstrate that the PIRL desorption is capable of extracting tissue molecular content in a state that is not drastically different from conventional methods
of molecular extraction for MS analysis, we compared the LC elution profiles of the laser plume (used in PIRL-MS to differentiate tissues) to that of the non-laser sampled tissue (used in conventional lipid MS studies), both subjected to identical chemical extraction conditions for LC. As shown in Supplementary Fig. S7, the same species dominated both elution profiles. This close match indicates that the proposed LC/MS method is a valid tool to identify MB classifying molecules as the PIRL-MS differentiation of MB subgroups appears to be based on biologically relevant molecules. Table 3 summarizes the lipid assignments for 10 molecules robustly identified via targeted analysis that contribute to MB subgroup classification. These molecules are shown to strongly contribute to PCA-LDA separation (rank orders within top 10 in each linear dimension). As seen here, the differentiation is based on a variety of lipid classes such as ceramides, phosphatidylethanolamines and phosphatidylcholines.

Discussion

Here, we provide evidence that, upon translation, PIRL-MS technology with its hand-held sampling probe will provide intraoperative MB subgrouping. This information could now influence the extent of resection and hence patient outcomes through predicting risk of relapse and likelihood of favorable response to adjuvant therapy. The utility of the model developed here using frozen tissue for real-time analysis of fresh surgical specimens is to be evaluated. However, to further assess the potential for clinical utility we also undertook an analysis of previously frozen surgical specimens sampled with PIRL-MS for a measure of concordance for spatially invariant MB subgroup assignment results. As illustrated in Supplementary Information, an average intrasample spatially invariant assignment rate of upwards of 90% is possible with PIRL-MS, where the results of the subgroup determinations do not depend on the location of the sampled site on the surface of the tumor. The high confidence seen for spatially invariant sampling results is an important practical attribute that makes PIRL-MS analysis robust in the context of spatially varying sites of biopsy. In much the same way that the full impact of genomic identification of MB subgroups as a risk stratification tool described above (9) was not necessarily envisioned at inception, we are unable to provide literature evidence as to how the ability to determine MB subgroups on intrasurgical timescales can be leveraged to provide personalized surgical treatments to patients with MB in the current standard of care. However, we are able to highlight a number of possibilities. For example, where the risk of neurologic morbidity is high and MB subgroup information suggests a good response to adjuvant therapy and a low chance for relapse, the surgeon may choose a less aggressive approach to resection. Likewise, in the case of MB patients belonging to tumor subgroups with poor prognosis, for example metastatic Group 4 patients, who do not seem to benefit from extensive resection due to the extensive leptomeningeal dissemination, the surgeon may choose a less aggressive approach to favor quality of life (38). In a similar vein, MB patients with incomplete initial resection have been traditionally regarded as high risk (>1.5 cm² of residual tumor present after surgery), and have been subjected to adjuvant chemotherapy and high-dose radiotherapy (if >3 years of age; ref. 38). Therefore, low-risk patients with a survival >90% such as nonmetastatic WNT patients based on the molecular risk stratification (9) potentially benefit from less aggressive surgery, especially if the possibility of significant neurologic morbidity due to aggressive resection in the posterior fossa is considered to be high. The availability of subgroup information during surgery may be crucial in these cases, as it could allow the neurosurgeon to adjust the extent of tumor resection according to the most favorable subgroup-based outcome information.

This work additionally highlights the utility of small molecule tissue profiling with PIRL-MS in tumor classification as a complementary tool to transcriptomic or genomic approaches currently in use for tumor subgroup identification, and further tumor subtype classifications. Although the lipidome and metabolome lack a one-to-one correspondence to the genome, our technique adds to the plethora of rapid ambient mass spectrometric methods of metabolomic profiling reported to classify tumor types in a manner consistent with genetic profiling (20). To better rationalize the involvement of the classes of lipid summarized in Table 3 in MB pathology, a future untargeted study aimed at elucidating all MB classifying lipids identifiable with MS is required. A deeper understanding of the lipid pathways may help explain the utility of PIRL-MS in MB classification. With this caveat, this study nevertheless adds to the growing list of ambient MS technologies that use lipid signatures to characterize cancer (22–26, 39, 40), and forms the basis of a new method to classify MB with the unparalleled advantage of speed without sacrificing specificity. Capitalizing on the significant alterations of the lipidome during oncogenesis (41), a myriad of mass spectrometry technologies have already used lipid signatures to classify cancerous tissues (39). Metabolic reprogramming in cancer cells is empirically shown to also have utility in further cancer classification into clinically relevant types and subtypes with MS (22–26, 39, 40).

Currently, RNA expression profiling utilizing NanoString methods utilizing the expression levels of only 22 MB subgroup specific signature genes (34) have been shown robust and promising to classify MB. In a similar vein, DNA methylation profiles have been shown to have utility in central nervous system tumor classification (42), including MB (43), offering advantages over NanoString (35). Further incorporation of genome-wide DNA methylation profiles has also been used to reveal additional MB subtypes (17). Although there is knowledge about the genes enriched in each MB subgroup (17), the link between the gene list empirically shown to have utility in NanoString classification, those significant in methylation profiling and the lipids identified herein with PIRL-MS requires additional work to make apparent. Nevertheless, a cursory examination of the reporter genes used in NanoString (35) indicates involvement of a variety of enzymes such as glutamate decarboxylase, glyceroaldehyde-3-phosphate dehydrogenase, and lactate dehydrogenase that play direct roles in small molecule metabolism. Therefore, it may not be entirely surprising that the PIRL-MS analysis of the tissue small molecules provides the same classification results as the genomic assays, albeit using a different set of molecular observables. Whether metabolic nuances provide sufficient contrast to capture grading of MB subgroups into additional subtypes (17) remains to be evaluated. In this quest, other non-ambient mass spectrometric analysis methods such as Matrix Assisted Laser Desorption Ionization Mass Spectrometry (MALDI-MS) can also be useful (44–49).

Similar to many other rapid mass spectrometry classification methods reviewed above [iKnife (28), Spider-Mass (29), MasSpec Pen (30)], PIRL-MS is likely to find utility
for *ex vivo* and *in situ*/*in vivo* tissue examination scenario (Supplementary Fig. S8) where its limited thermal and mechanical damage to regions outside the ablation zone (50) will be leveraged in adoption.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Authors’ Contributions**

Conception and design: T. Kyota, A. Aman, H.J. Ginsberg, A. Zarrine-Afsar

Development of methodology: M. Woolman, C.M. Kuzan-Fischer, I. Ferry, T. Kyota, A. Aman, H.J. Ginsberg, A. Zarrine-Afsar

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. Woolman, C.M. Kuzan-Fischer, I. Ferry, T. Kyota, D.G. Munoz, S. Das, A. Aman, M.D. Taylor, A. Zarrine-Afsar

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Woolman, C.M. Kuzan-Fischer, T. Kyota, M. Wu, D.G. Munoz, A. Aman, A. Zarrine-Afsar

Writing, review, and/or revision of the manuscript: M. Woolman, C.M. Kuzan-Fischer, I. Ferry, T. Kyota, M. Wu, D.G. Munoz, S. Das, A. Aman, J.T. Rutka, H.J. Ginsberg, A. Zarrine-Afsar

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): I. Ferry, B. Liu

Study supervision: A. Zarrine-Afsar

**Acknowledgments**

We are grateful to Craig Daniels, Jim Loukides (Hospital for Sick Children), Jeff O’Mara (Ontario Institute for Cancer Research), and Ori Rotstein (St. Michael’s Hospital) for assistance and advice. Authors thank Stacey Knutholtz, Medical Illustrator at The Hospital for Sick Children, Toronto, Canada, for preparation of setup schematics. This work received Foundation support from Princess Margaret Hospital (to A. Zarrine-Afsar) and St. Michael’s Hospital (to A. Zarrine-Afsar and H.J. Ginsberg). A. Zarrine-Afsar further acknowledges support from Natural Sciences and Engineering Research Council of Canada Discovery Grant Program (NSERC, RGPIN-2018-04611) for PIRL-MS platform development. Authors additionally thank STTARR Innovation Centre (www.sttarr.com) and its affiliated funders.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 31, 2018; revised February 13, 2019; accepted March 14, 2019; published first March 19, 2019.

**References**


Picosecond Infrared Laser Desorption Mass Spectrometry Identifies Medulloblastoma Subgroups on Intrasurgical Timescales

Michael Woolman, Claudia M. Kuzan-Fischer, Isabelle Ferry, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-18-3411

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2019/03/19/0008-5472.CAN-18-3411.DC1

Cited articles
This article cites 48 articles, 9 of which you can access for free at:
http://cancerres.aacrjournals.org/content/79/9/2426.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/79/9/2426.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/79/9/2426.
Click on "Request Permissions“ which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.